Elan and financials help ISEQ up

The ISEQ rose 55.5 points to 7574.24 this morning as the main players posted gains.

Elan was up 45c (3.8%) at €12.35 at 10.30am following news that it has agreed to sell the rights to its Prialt drug for the treatment of chronic pain in Europe to Eisai, while retaining the product rights in the United States.